Diagnostic tests provider Prevencio has developed a new multi-protein blood test HART CVE, in collaboration with Massachusetts General Hospital, to detect risk the of heart attack, stroke or cardiovascular death.

A study conducted to validate the test showed that it accurately identifies the risk of these cardiac disorders compared to commonly-used risk factors.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The new blood test was examined for its ability to detect one-year risk of having a heart attack, stroke, or cardiovascular death in more than 900 subjects.

"It was found that the test predicted with 97% accuracy (negative predictive value) that a low-risk patient would not have a heart attack or major cardiac event within one year."

Prevencio president and chief executive officer Rhonda Rhyne said: “Prevencio is honoured to work with Massachusetts General Hospital’s talented team of dedicated researchers to find safer, more accurate and more affordable ways to identify and treat millions of cardiac patients.

“The American Heart Association recently issued a Scientific Statement on the transformative impact of proteomics on cardiovascular health and disease, and we are pleased to be at the forefront of using multi-protein tests to improve cardiovascular care.”

It was found that the test predicted with 97% accuracy (negative predictive value) that a low-risk patient would not have a heart attack or major cardiac event within one year, when the test score was categorised into low-risk and high-risk.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the study's principal investigator James Januzzi, the test can be useful for those patients with suspected or known stable heart disease, for which there are very few prognostic risk models.

Prevencio is also developing another multi-protein blood test HART CAD to diagnose obstruction of the coronary arteries.

With plans to conduct regulatory trials next year and submit for European and FDA approvals in 2018-2019, it is expected that the HART CVE and HART CAD tests will be available for use by 2019.